Lamotrigine
Lamotrigine is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Lamotrigine; Generic name: LAMOTRIGINE; Drug class: Anti-epileptic Agent [EPC].
| Brand name | Lamotrigine |
|---|---|
| Generic name | LAMOTRIGINE |
| Drug class | Anti-epileptic Agent [EPC] |
| Manufacturer | Preferred Pharmaceuticals, Inc. |
| Used for | 1 INDICATIONS AND USAGE Lamotrigine tablets are indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic (PGTC) seizures. • generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older : Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard t |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Dosing is based on concomitant medications, indication, and patient age. ( 2.1 , 2.2 , 2.3 , 2.4 ) • To avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded. ( 2.1 ) • Do not restart lamotrigine tablets in patients who discontinued due to rash unless the potential benefits clearly outweigh the risks. ( 2.1 , 5.1 ) • Adjustments to maintenance doses will be necessary in most patients starting or stopping |
| Warnings | WARNING: SERIOUS SKIN RASHES WARNING: SERIOUS SKIN RASHES See full prescribing information for complete boxed warning. • Cases of life-threatening serious rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and/or rash-related death have been caused by lamotrigine. The rate of serious rash is greater in pediatric patients than in adults. Additional factors that may increase the risk of rash include: o coadministration with valproate. o exceeding recommended initial dose of |
| Active ingredient(s) | LAMOTRIGINE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16323699-9bf8-43c7-b3aa-589156377872 |